{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:08:21Z","timestamp":1791824901357,"version":"4.3.4"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones, have been developed and approved for clinical use worldwide. Inactivated vaccines are produced using a proven technology that is widely used for the production of vaccines for the prevention and control of infectious diseases, including influenza and poliomyelitis. The development of inactivated whole-virion vaccines commonly includes several stages: the production of cellular and viral biomass in cell culture; inactivation of the virus; filtration and ultrafiltration; chromatographic purification of the viral antigen; and formulation with stabilizers and adjuvants. In this study, the suitability of four resins for Size-Exclusion Chromatography was investigated for the purification of a viral antigen for the human COVID-19 vaccine.<\/jats:p>","DOI":"10.3390\/vaccines10060949","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T22:54:52Z","timestamp":1655679292000},"page":"949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography"],"prefix":"10.3390","volume":"10","author":[{"given":"Anastasia A.","family":"Kovpak","sequence":"first","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia N.","family":"Piniaeva","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg A.","family":"Gerasimov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina O.","family":"Tcelykh","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayya Y.","family":"Ermakova","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-8361","authenticated-orcid":false,"given":"Anna N.","family":"Zyrina","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-1112","authenticated-orcid":false,"given":"Dmitry V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury Y.","family":"Ivin","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubov I.","family":"Kozlovskaya","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydar A.","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_2","unstructured":"(2022, April 13). WHO. Available online: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"ref_3","unstructured":"(2022, April 13). ICTV. Available online: https:\/\/talk.ictvonline.org\/taxonomy\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bit.24798","article-title":"Scale-down of the inactivated polio vaccine production process","volume":"110","author":"Thomassen","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/j.vaccine.2011.04.124","article-title":"An international technology platform for influenza vaccines","volume":"29","author":"Hendriks","year":"2011","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-008-0292-3","article-title":"Expression of SARS-coronavirus spike glycoprotein in Pichia pastoris","volume":"38","author":"Chuck","year":"2009","journal-title":"Virus Genes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"618615","DOI":"10.3389\/fbioe.2020.618615","article-title":"Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct","volume":"8","author":"Bierig","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2427(02)00135-6","article-title":"Specific mucosal IgA immunity in turkey poults infected with turkey coronavirus","volume":"88","author":"Loa","year":"2002","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1080\/22221751.2020.1855945","article-title":"Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1080\/22221751.2021.1971569","article-title":"Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies","volume":"10","author":"Kozlovskaya","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ishmukhametov, A.A., Siniugina, A.A., Yagovkina, N.V., Kuzubov, V.I., Zakharov, K.A., Volok, V.P., Dodina, M.S., Gmyl, L.V., Korotina, N.A., and Theodorovich, R.D. (2022). Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: A multicenter, randomized, double-blind, placebo-controlled phase I\/II clinical trial. medRxiv.","DOI":"10.1101\/2022.02.08.22270658"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijid.2020.07.024","article-title":"Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak","volume":"99","author":"Kozlovskaya","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_19","first-page":"7","article-title":"The Lowry method for protein quantitation","volume":"32","author":"Waterborg","year":"1994","journal-title":"Methods Mol. Biol."},{"key":"ref_20","unstructured":"(2022, April 13). Registration of Drugs in Russia and EAEU (CIS). Available online: https:\/\/pharmacopoeia.ru\/ofs-1-2-3-0012-15-opredelenie-belka\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jemt.23931","article-title":"Structural characterization of \u03b2-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles","volume":"85","author":"Bagrov","year":"2022","journal-title":"Microsc. Res. Tech."},{"key":"ref_23","unstructured":"European Directorate for the Quality of Medicines & Healthcare (2022). European Pharmacopoeia (Ph. Eur.), EDQM. [10th ed.]."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/6\/949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:31:48Z","timestamp":1760139108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/6\/949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["vaccines10060949"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10060949","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}